BlackRock Inc. boosted its position in National Research Co. (NASDAQ:NRC) by 7.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 709,948 shares of the company’s stock after acquiring an additional 49,361 shares during the quarter. BlackRock Inc. owned 2.86% of National Research worth $40,885,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NRC. Advisor Group Inc. grew its stake in shares of National Research by 17.8% during the second quarter. Advisor Group Inc. now owns 2,263 shares of the company’s stock valued at $131,000 after buying an additional 342 shares during the last quarter. Quantamental Technologies LLC grew its stake in shares of National Research by 125.2% during the second quarter. Quantamental Technologies LLC now owns 743 shares of the company’s stock valued at $43,000 after buying an additional 413 shares during the last quarter. Bank of Montreal Can bought a new position in shares of National Research during the second quarter valued at about $59,000. Charles Schwab Investment Management Inc. grew its stake in shares of National Research by 2.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 67,579 shares of the company’s stock valued at $3,892,000 after buying an additional 1,396 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of National Research by 13.8% during the second quarter. Swiss National Bank now owns 23,100 shares of the company’s stock valued at $1,330,000 after buying an additional 2,800 shares during the last quarter. 36.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:NRC opened at $58.18 on Friday. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 1.24. The stock’s 50-day moving average price is $61.39 and its 200-day moving average price is $41.10. The stock has a market capitalization of $1.44 billion, a P/E ratio of 55.94 and a beta of 0.77. National Research Co. has a 12-month low of $35.65 and a 12-month high of $68.86.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.19 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.31%. National Research’s dividend payout ratio is currently 73.08%.
Separately, ValuEngine cut National Research from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
In other news, major shareholder Amandla Mk Trust sold 500,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $60.50, for a total transaction of $30,250,000.00. Also, President Steven D. Jackson sold 10,000 shares of the stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $88.22, for a total transaction of $882,200.00. Over the last quarter, insiders have sold 864,692 shares of company stock valued at $53,606,063. 4.50% of the stock is currently owned by company insiders.
National Research Profile
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.